Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Regulatory Routine +

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of (Pr)OKEDI(TM) (Risperidone for extended-release injectable suspension) for the treatment of schizophrenia

Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

By The Northwire Desk — AI Analysis Jun 09, 2026 · 08:00 BHC · 7.16 BAUSCH HEALTH COMPANIES INC.
Executive Summary
  • Bausch Health, Canada Inc. signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) to secure public drug plan coverage for PrOKEDI (risperidone extended-release injectable suspension) for schizophrenia.
  • The LOI follows positive Phase 3 PRISMA-3 trial data showing significant symptom improvement versus placebo and a 12-month extension confirming sustained disease stability.
  • Next steps involve finalizing Product Listing Agreements with federal, provincial, and territorial public drug plans to enable patient access.
  • This is a standard commercial/regulatory milestone for the Canadian pharmaceutical portfolio, not a transformative corporate event.
Material Impact
  • The PrOKEDI LOI is a positive commercial milestone for the Canadian portfolio but does not alter the company's fundamental debt profile, pipeline trajectory, or tariff exposure.
  • The stock had already declined -6.5% into the print, indicating that skepticism regarding the RED-C failure, tariff headwinds, and leverage was already discounted.
  • The news is Routine - Positive. It provides incremental commercial visibility but lacks the scale to re-rate the business or meaningfully impact the ~$2.65B market cap.
BHC · Price
Company Overview
  • Bausch Health is a diversified global pharmaceutical and healthcare company with segments in gastroenterology (Salix), aesthetics (Solta Medical), eye health (Bausch + Lomb), international pharma, and diversified products.
  • Strategic focus includes debt reduction, pipeline development (Larsucosterol for alcohol-associated hepatitis), and geographic expansion in China via the Shibo acquisition.
  • The company is navigating a complex transition from legacy litigation settlements to a leaner, debt-focused operating model while preparing for Xifaxan loss-of-exclusivity in 2028.
Read the original news release →

More from BAUSCH HEALTH COMPANIES INC.

May 28, 2026 · 16:15

Solta Trademark Win Reinforces China Growth Narrative Amidst Elevated Debt Costs and Xifaxan LOE Clock

Production / Operations Apr 29, 2026 · 16:05

BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

Earnings Apr 14, 2026 · 08:00

Biafine Launch Fails to Offset Clinical Failure and Debt Burden

Other Feb 23, 2026 · 17:59

Bausch Health launches Clear + Brilliant in Canada

Regulatory Feb 23, 2026 · 08:00

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant(TM) Touch Laser in Canada

Production / Operations Feb 18, 2026 · 16:05

BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

Earnings